22:11 on September 17, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock fluctuated and the stock price plummeted by 10.55%. As of press time, the stock was trading at US $0.640 per share, with a turnover of 2925 shares, a turnover rate of 0.01% and an amplitude of 3.38%.
Recent earnings data show that the stock achieved operating income of $2362.00, net profit of-$281603.00, earnings per share of-$0.01and gross profit of $419.00, with a price-to-earnings ratio of-84.34 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry in which WUHAN GENERAL GP shares are located in the US OTC market, the overall decline was 0.71 per cent. Among its related stocksGrifols Sa、Flora Growth Corp.、Amryt Pharma Plc (New)The increase is relatively large.Teligent Inc New、Grove, Inc.、Zynerba Pharmaceuticals IncRelatively active, with turnover rates of 1.24%, 0.80% and 0.80% respectively. The related stocks with larger amplitudes areClever Leaves Holdings Inc C/Wts 18 + 12 * 2025 (To Pur Com)、 Grove, Inc. 、Petros Pharmaceuticals IncThe amplitudes were 9.16%, 7.48% and 6.86%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )